1. World Health Organization, International Agency for Research on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Pharmaceuticals, Volume 100 (A), Combined Estrogen- Progestogen Contraceptives, Lyon: IARC, 2012:311: „There is sufficient evidence in humans for the carcinogeniciti of combined estrogen−progestogen oral contraceptives. Combined estrogen−progestogen oral contraceptives cause cancer of the breast, in-situ and invasive cancer of the uterine cervix, and cancer of the liver”.
  2. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. The New England Journal of Medicine. 2017 Dec 7;377(23):2228-2239.
  3. Imkampe AK, Bates T. Correlation of age at oral contraceptive pill start with age at breast cancer diagnosis. The Breast Journal. 2012 Jan-Feb;18(1):35-40.
  4. International Collaboration of Epidemiological Studies of Cervical Cancer: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 November; 370 (9599):1609-1621.
  5. Moreno V, Bosch FX, Muñoz N. et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002 Mar 30;359(9312):1085-92.
  6. Petrick JL, McMenamin ÚC, Zhang X, et al. Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank. British Journal of Cancer. 2020 Jul;123(2):316-324.
  7. Hsing AW, Hoover RN, McLaughlin JK. et al. Oral contraceptives and primary liver cancer among young women. Cancer Causes Control. 1992 Jan;3(1):43-8.
  8. Andersen L, Friis S, Hallas J, et al. Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. British Journal of Clinical Pharmacology. 2015;79(4):677-684.
  9. Sun Q, Sun H, Cong L, Zheng Y, et al. Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis. Clinical Epidemiology. 2020;12:1183-1203.
  10. Cervenka I, Mahamat-Saleh Y, Savoye I, et al. Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study. International Journal of Cancer. 2018 Nov 15;143(10):2390-2399.
  11. Оshyvalova ОО, Ziukov OL, Gurianov VG. Prognostic model of skin cancer risk assessment. Wiadomości Lekarskie. 2019;72(5 cz 1):817-822.
  12. Kuklinski LF, Zens MS, Perry AE, et al. Sex hormones and the risk of keratinocyte cancers among women in the United States: a population-based case-control study. International Journal of Cancer. 2016 Jul;139(2):300-309.
  13. Lee E, Horn-Ross PL, Rull RP. et al. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. American Journal of Epidemiology. 2013 Nov 1;178(9):1403-13.
  14. Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. American Journal of Epidemiology. 2018;187(8):1630-1641.
  15. Brinton LA, Thistle JE, Liao LM, Trabert B. Epidemiology of vulvar neoplasia in the NIH-AARP Study. Gynecologic Oncology. 2017 May;145(2):298-304.
  16. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception: Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995 Dec 16;346(8990):1575-82.
  17. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. The BMJ. 2013 Sep 12;347:f5298.
  18. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997 Apr 26;349(9060):1202-9.
  19. Lidegaard Ø, Løkkegaard E, Jensen A. et al. Thrombotic stroke and myocardial infarction with hormonal contraception. The New England Journal of Medicine. 2012 Jun 14;366(24):2257-66.
  20. Xu Z, Li Y, Tang S, Huang X, Chen T. Current use of oral contraceptives and the risk of first-ever ischemic stroke: A meta-analysis of observational studies. Thrombosis Research. 2015 Jul;136(1):52-60.
  21. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996 Aug 24;348(9026):498-505.
  22. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives–an approach to specifying rates. European Journal of Epidemiology. 2005;20(6):509-16.
  23. Keenan L, Kerr T, Duane M, Van Gundy K. Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. Linacre Q. 2018 Nov;85(4):470-477.
  24. Deac OM, Mills JL, Shane B, et al. Tryptophan Catabolism and Vitamin B-6 Status Are Affected by Gender and Lifestyle Factors in Healthy Young Adults. The Journal of Nutrition. 2015 Apr;145(4):701-707.
  25. Meier TB, Drevets WC, Teague TK, et al. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression. Brain, Behavior, and Immunity. 2018 Jan;67:59-64.
  26. Del Río JP, Alliende MI, Molina N, et al. Steroid Hormones and Their Action in Women’s Brains: The Importance of Hormonal Balance. Frontiers in Public Health. 2018;6:141.
  27. Coelingh Bennink HJT, Zimmerman Y, Laan E, et al. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects. Contraception. 2017 Nov;96(5):322-329.
  28. Petersen N, Kearley NW, Ghahremani DG, et al. Effects of oral contraceptive pills on mood and magnetic resonance imaging measures of prefrontal cortical thickness. Molecular Psychiatry. 2021 Jan 8; 917–926.
  29. Petersen N, Touroutoglou A, Andreano JM, Cahill L. Oral contraceptive pill use is associated with localized decreases in cortical thickness. Human Brain Mapping.2015;36(7):2644-54.
  30. Lisofsky N, Riediger M, Gallinat J, et al. Hormonal contraceptive use is associated with neural and affective changes in healthy young women. NeuroImage. 2016 Jul 1;134:597-606.
  31. Fruzzetti F, Fidecicchi T. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clinical Drug Investigation. 2020 Dec;40(12):1097-1106.
  32. Larsen SV, Köhler-Forsberg K, Dam VH, et al. Oral contraceptives and the serotonin 4 receptor: a molecular brain imaging study in healthy women. Acta Psychiatrica Scandinavica. 2020 Oct;142(4):294-306.
  33. Lewis CA, Kimmig AS, Zsido RG, et al. Effects of Hormonal Contraceptives on Mood: A Focus on Emotion Recognition and Reactivity, Reward Processing, and Stress Response. Current Psychiatry Reports. 2019;21(11):115.
  34. Gingnell M, Engman J, Frick A. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill–a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. Psychoneuroendocrinology. 2013 Jul;38(7):1133-44.
  35. Wiréhn AB, Foldemo A, Josefsson A, Lindberg M. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. European Journal of Contraception and Reproductive Health Care. 2010 Feb;15(1):41-7.
  36. Young EA, Kornstein SG, Harvey AT, et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology. 2007;32(7):843-853.
  37. de Wit AE, Booij SH, Giltay EJ, et al. Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. JAMA Psychiatry. 2020 Jan 1;77(1):52-59.
  38. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018;13(3):e0194773.
  39. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016 Nov 1;73(11):1154-1162.
  40. Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception. 2012 Apr;17(2):106-18.
  41. American Academy of Child and Adolescent Psychiatry. Suicide in Children and Teens. 2018. https://www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/FFF-Guide/Teen-Suicide-010.aspx. Accessed 29 Jan 2021.
  42. Wiréhn AB, Foldemo A, Josefsson A, Lindberg M. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, 2010 Feb;15(1):41-7.
  43. Pérez-López FR, Pérez-Roncero GR, López-Baena MT, et al. Hormonal contraceptives and the risk of suicide: a systematic review and meta-analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2020 Aug;251:28-35.
  44. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. The American Journal of Psychiatry. 2018 Apr 1;175(4):336-342.
  45. Charlton BM, Rich-Edwards JW, Colditz GA. Et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ : British Medical Journal. 2014 Oct 31;349:g6356.
  46. Hampson E. A brief guide to the menstrual cycle and oral contraceptive use for researchers in behavioral endocrinology. Hormones and Behavior. 2020 Mar;119:104655.
  47. Agulles Simó P. Efecto Abortivo de los Anticonceptivos Hormonales: Una Revisión [Abortifacient effect of hormonal contraceptives: a review]. Cuadernos de bioética : revista oficial de la Asociación Española de Bioética y Ética Médica. 2015 Jan-Apr;26(86):69-109.
  48. Talukdar N , Bentov Y, Chang PT, et al. Effect of long-term combined oral contraceptive pill use on endometrial thickness. Obstetrics and Gynecology. 2012 Aug;120(2 Pt 1):348-54.
  49. Dinger JC et al. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. America Journal of Obstetrics and Gynecology. 2009 Sep; 201:263.e1.
  50. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention National Center for Health Statistics. Use of Contraception in the United States: 1982–2008. August 2010. http://www.cdc.gov/nchs/data/series/sr_23/ /sr23_029.pdf. Accessed 29 jan 2021.
  51. Pombo-de-Oliveira MS. Maternal hormonal contraception and childhood leukaemia. Lancet Oncology. 2018 Oct;19(10):1261-1262
  52. Taye M, Afework M, Fantaye W, et al. Factors associated with congenital anomalies in Addis Ababa and the Amhara Region, Ethiopia: a case-control study. BMC Pediatrics. 2018;18(1):142.
  53. Ahmed H. Maternal Exposure to Different Types of Hormonal Compounds from Oral Contraceptives in the First Trimester of Pregnancy and Its Association with Birth Defects. The University of Texas School of Public Health. Texas Medical Center Dissertations. 2017. https://www.researchgate.net/publication/318813561.
  54. Aynalem F. Determinants of Neural Tube Defect Among Children, at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, 2018 a Case Control Study [master’s thesis]. Addis Ababa, Ethiopia: Addis Ababa University; 2018
  55. Yin Z, Xu W, Xu C, et al. A population-based case-control study of risk factors for neural tube defects in Shenyang, China. Child’s Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery. 2011;27(1):149–154.
  56. Li L, Li M, Lu J, et al. Prenatal Progestin Exposure Is Associated With Autism Spectrum Disorders. Frontiers in Psychiatry. 2018;9:611.
  57. Ahmed H. Maternal Exposure to Different Types of Hormonal Compounds from Oral Contraceptives in the First Trimester of Pregnancy and Its Association with Birth Defects. The University of Texas School of Public Health. Texas Medical Center Dissertations. 2017. https://www.researchgate.net/publication/318813561.
  58. Given JE, Loane M, Garne E, et al. Gastroschisis in Europe – A Case-malformed-Control Study of Medication and Maternal Illness during Pregnancy as Risk Factors. Paediatric and Perinatal Epidemiology. 2017 Nov;31(6):549-59.
  59. Robledo-Aceves M, Bobadilla-Morales L, Mellín-Sánchez EL, et al. Prevalence and risk factors for gastroschisis in a public hospital from west México. Congenital Anomalies. 2015 May;55(2):73-80.
  60. Waller DK, Gallaway MS, Taylor LG, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. Epidemiology. 2010 Mar;21(2):232-9.
  61. Ahmed H. Maternal Exposure to Different Types of Hormonal Compounds from Oral Contraceptives in the First Trimester of Pregnancy and Its Association with Birth Defects. The University of Texas School of Public Health. Texas Medical Center Dissertations. 2017. https://www.researchgate.net/publication/318813561.
  62. Waller DK, Gallaway MS, Taylor LG, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. Epidemiology. 2010 Mar;21(2):232-9.
  63. Ray A, Hong CS, Feingold E, et al. Maternal Telomere Length and Risk of Down Syndrome: Epidemiological Impact of Smokeless Chewing Tobacco and Oral Contraceptive on Segregation of Chromosome 21. Public Health Genomics. 2016;19(1):11-8.
  64. Ghosh S, Hong CS, Feingold E. et al., Epidemiology of Down syndrome: new insight into the multidimensional interactions among genetic and environmental risk factors in the oocyte. American Journal of Epidemiology. 2011 Nov 1;174(9):1009-16.
  65. Martínez-Frías ML, Bermejo E, Rodríguez-Pinilla E, et al. Periconceptional exposure to contraceptive pills and risk for Down syndrome. Journal of Perinatology : Official Journal of the California Perinatal Association. 2001 Jul-Aug;21(5):288-92.
  66. van Rooij IA, van der Zanden LF, Brouwers MM, et al., Risk factors for different phenotypes of hypospadias: results from a Dutch case-control study. BJU International. 2013 Jul;112(1):121-8.
  67. Lind JN, Tinker SC, Broussard CS, et al. Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiology and Drug Safety. 2013;22(7):783-93.
  68. Hemmingsen CH, Kjaer SK, Jezek AH, et al. Maternal use of hormonal contraception and risk of childhood ADHD: a nationwide population-based cohort study. European Journal of Epidemiology. 2020 Sep;35(9):795-805.
  69. Vainio H. Carcinogenesis and teratogenesis may have common mechanisms. Scandinavian Journal of Work, Environment & Health. 1989 Feb;15(1):13-7.
  70. Janitz AE, Neas BR, Campbell JE, et al. Childhood cancer in children with congenital anomalies in Oklahoma, 1997 to 2009. Clinical and Molecular Teratology. 2016;106(7):633–642.
  71. Botto LD, Flood T, Little J, et al. Cancer risk in children and adolescents with birth defects: a population-based cohort study. PLoS One. 2013;8(7):e69077.
  72. Erjaee A, Niknam M, Sadeghi A, et al. A Significant Breakthrough in the Incidence of Childhood Cancers and Evaluation of its Risk Factors in Southern Iran. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology.2017;38(2):158–164.
  73. Pombo-de-Oliveira MS. Maternal hormonal contraception and childhood leukaemia. Lancet Oncology. 2018 Oct;19(10):1261-1262
  74. Hargreave M, Mørch LS, Andersen KK et al. Maternal use of hormonal contraception and risk of childhood leukaemia: a nationwide, population-based cohort study. The Lancet. Oncology. 2018 Oct;19(10):1307-1314.
  75. Ajrouche R, Rudant J, Orsi L, et al. Maternal reproductive history, fertility treatments and folic acid supplementation in the risk of childhood acute leukemia: the ESTELLE study. Cancer Causes Control. 2014 Oct;25(10):1283-93.
  76. Shu XO, Han D, Severson RK, et al. Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control. 2002 Feb;13(1):15-25.
  77. Schüz J, Kaletsch U, Meinert R. Risk factors for neuroblastoma at different stages of disease. Results from a population-based case-control study in Germany. Journal of Clinical Epidemiology. 2001 Jul;54(7):702-9.
  78. Wang Q, Würtz P, Auro K, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. International Journal of Epidemiology. 2016;45(5):1445-1457.
  79. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013;27(1):13-24.
  80. Allaway HCM, Misra M, Southmayd EA, et al. Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?. Frontiers in Endocrinology. 2020;11:334.
  81. Rios-Avila L, Coats B, Chi YY, et al. Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives on these processes. The Journal of Nutrition. 2015;145(1):87-95.
  82. Sarabi MM, Ghareghani P, Khademi F, Zal F. Oral Contraceptive Use May Modulate Global Genomic DNA Methylation and Promoter Methylation of APC1 and ESR1. Asian Pacific Journal of Cancer Prevention : APJCP. 2017;18(9):2361-2366.
  83. Campesi I, Sanna M, Zinellu A. et al. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function. Biology of Sex Differences. 2012 Jan 27;3:4.
  84. Kamp F, Rodrigues TSL, Donangelo CM. Effect of oral contraceptive use and zinc supplementation on zinc, iron and copper biochemical indices in young women. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism. 2011; 6(6):e253-e258.
  85. Wakeman, M. A Review of the Effects of Oral Contraceptives on Nutrient Status, with Especial Consideration to Folate in UK. Journal of Advances in Medicine and Medical Research. 2019;30(2):1-17.
  86. Mtango NR, Potireddy S, Latham KE. Oocyte quality and maternal control of development. International Review of Cell and Molecular Biology. 2008;268:223-290.
  87. Genuis S, Genuis R. Preconception Care: A New Standard of Care within Maternal Health Services. BioMed Research International. 2016; 2016:1-30.
  88. Keefe D, Kumar M, Kalmbach K. Oocyte competency is the key to embryo potential. Fertility and Sterility. 2015 Feb;103(2):317-22.
  89. Ashworth CJ, Toma LM, Hunter MG. Nutritional effects on oocyte and embryo development in mammals: implications for reproductive efficiency and environmental sustainability. Biological Sciences. 2009;364(1534):3351-3361.
  90. Mtango NR, Potireddy S, Latham KE. Oocyte quality and maternal control of development. International Review of Cell and Molecular Biology. 2008;268:223-290.
  91. Varghese AC, Ly KD, Corbin C, et al. Oocyte developmental competence and embryo development: impact of lifestyle and environmental risk factors. Reproductive Biomedicine Online. 2011 May;22(5):410-20.
  92. Sreerangaraja Urs DB, Wu WH, Komrskova K, et al. Mitochondrial Function in Modulating Human Granulosa Cell Steroidogenesis and Female Fertility. International Journal of Molecular Sciences. 2020;21(10):3592.
  93. Uyar A, Torrealday S, Seli E. Cumulus and granulosa cell markers of oocyte and embryo quality. Fertility and Sterility. 2013 Mar 15;99(4):979-97.
  94. Hoshino Y. Updating the markers for oocyte quality evaluation: intracellular temperature as a new index. Reproductive Medicine and Biology. Reproductive Medicine and Biology. 2018 Sep 27;17(4):434-441.
  95. Mtango NR, Potireddy S, Latham KE. Oocyte quality and maternal control of development. International Review of Cell and Molecular Biology. 2008;268:223-290.
  96. Mtango NR, Potireddy S, Latham KE. Oocyte quality and maternal control of development. International Review of Cell and Molecular Biology. 2008;268:223-290.
  97. WHO (World Health Organization)/UNEP (United Nations Environment Programme) The State-of-the-Science of Endocrine Disrupting Chemicals – 2012 (Bergman Å, Heindel JJ, Jobling S, Kidd KA, Zoeller RT, eds). Geneva:UNEP/WHO. 2013. http://www.who.int/ceh/publications/endocrine/en/index.html. Accessed 12 November 2018.
  98. Yin Z, Xu W, Xu C, et al. A population-based case-control study of risk factors for neural tube defects in Shenyang, China. Child’s Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery. 2011;27(1):149–154.
  99. Waller DK, Gallaway MS, Taylor LG, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. Epidemiology. 2010 Mar;21(2):232-9.
  100. Kasan, P. N., Andrews. J., Oral contraception and congenital abnormalities. British Journal of Obstetrics and Gynaecology. 1980 Jul;87(7):545-51.
  101. Hankus M, Kazek B, Paprocka J, et al. Preconception Risk Factors for Autism Spectrum Disorder – A Pilot Study. Brain Sciences. 2020;10(5):293
  102. Ahmed H. Maternal Exposure to Different Types of Hormonal Compounds from Oral Contraceptives in the First Trimester of Pregnancy and Its Association with Birth Defects. The University of Texas School of Public Health. Texas Medical Center Dissertations. 2017. https://www.researchgate.net/publication/318813561.
  103. Waller DK, Gallaway MS, Taylor LG, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. Epidemiology. 2010 Mar;21(2):232-9.
  104. Shawky RM, Elsobky E, Elsayed SM, et al. Maternal risk factors in young Egyptian mothers of Down syndrome. Egyptian Journal of Medical Human Genetics. 2008 Nov; 10(2):144-152.
  105. Lejeune J, Prieur M. Oral contraceptives and trisomy 21. A retrospective study of 730 cases. Annales de Génétique. 1979 Jun;22(2):61-6.
  106. Hemmingsen CH, Kjaer SK, Jezek AH, et al. Maternal use of hormonal contraception and risk of childhood ADHD: a nationwide population-based cohort study. European Journal of Epidemiology. 2020 Sep;35(9):795-805.
  107. Pombo-de-Oliveira MS. Maternal hormonal contraception and childhood leukaemia. Lancet Oncology. 2018 Oct;19(10):1261-1262
  108. Gholami A, Salarilak S, Hejazi S, Khalkhali HR. Parental risk factors of childhood acute leukemia: a case-control study. Journal of Research in Health Sciences. 2011 Nov 4;11(2):69-76.
  109. Shu XO, Han D, Severson RK, et al. Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control. 2002 Feb;13(1):15-25.
  110. Henriette Van Steensel-Moll et al. Are maternal fertility problems related to childhood leukaemia? International Journal of Epidemiology. 1985 Dec; 14(4):555-559.
  111. Linet MS, Gridley G, Cnattingius S, et al. Maternal and perinatal risk factors for childhood brain tumors (Sweden). Cancer Causes Control. 1996 Jul;7(4):437-48.
  112. Mikkelsen EM, Riis AH, Wise LA., et al. Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study. Human Reproduction (Oxford, England). 2013 Feb;28(5):1398-1405.
  113. Chasan-Taber L, Willett WC, Stampfer MJ, et al. Oral contraceptives and ovulatory causes of delayed fertility. American Journal of Epidemiology. 1997 Aug 1;146(3):258-65.
  114. Nassaralla CL, Stanford JB, Daly KD, et al. Characteristics of the menstrual cycle after discontinuation of oral contraceptives. Journal of Women’s Health. 2011 Feb;20(2):169-77.
  115. Talukdar N, Bentov Y, Chang PT, et al. Effect of long-term combined oral contraceptive pill use on endometrial thickness. Obstetrics and Gynecology. 2012 Aug;120(2 Pt 1):348-54.
  116. Letourneau JM, Cakmak H, Quinn M, Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield. Journal of Assisted Reproduction and Genetics. 2017;34(9):1137-1144.
  117. Birch Petersen K, Hvidman HW, Forman JL. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Human Reproduction. 2015 Oct;30(10):2364-75.
  118. Kallio S, P J, FRuokonen A, Vaskivuo T, et al. AMH levels decrease in women using combined contraception independently of administration route. Fertility and Sterility. 2013;99:1305–1310.
  119. Bentzen JG, Forman JL, Pinborg A., et al. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reproductive Biomedicine Online. 2012 Dec;25(6):612-9.
  120. Ulcova-Gallova Z, Bibkova K, Micanova Z, et al. Possible Effect of Extended Use of Hormonal Contraception on Increased Levels of Antiphospholipid Antibodies in Infertile Women. Geburtshilfe und Frauenheilkunde. 2015;75(3):251-254.
  121. Jones RK. Beyond birth control: the overlooked benefits of oral contraceptive pills. New York, NY: Guttmacher Institute; 2011.
  122. Black A, Guilbert E, Costescu D, et al. No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. Journal of Obstetrics and Gynaecology Canada : JOGC = Journal d’obstétrique et gynécologie du Canada : JOGC. 2017 Apr;39(4):229-268.e5.
  123. Raidoo, S., Kaneshiro, B. Unscheduled Bleeding on Hormonal Contraceptives: Pathophysiology, Evaluation, and Management Options. Current Obstetrics and Gynecology Reports. 2017: 118–125.
  124. Phadnis SV, Walker, PG.. Modern management of postcoital and intermenstrual bleeding. Trends in Urology, Gynaecology & Sexual Health. 2008;13(4):24-27.
  125. Patient. Intermenstrual and Postcoital Bleeding. Jarvis S. 2020. https://patient.info/doctor/intermenstrual-and-postcoital-bleeding. Accessed 28 November 2020.
  126. Tarney CM, Han J. Postcoital bleeding: a review on etiology, diagnosis, and management. Obstetrics and gynecology international. 2014;2014:192087.
  127. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sexually Transmitted Diseases. 2004 Sep;31(9):561-7.
  128. Bright PL, Norris Turner A, Morrison CS, et al. Hormonal contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011;84(5):512-519.
  129. NHS Manchester University. Cervical Ectopy (Cervical Erosion). Review: Date June 2020. https://mft.nhs.uk/app/uploads/sites/4/2018/04/18-28-Cervical-Ectopy-June-2018.pdf. Accessed 01 Feb 2021.
  130. De Sanctis V, Rigon F, Bernasconi S, et al. Age at Menarche and Menstrual Abnormalities in Adolescence: Does it Matter? The Evidence from a Large Survey among Italian Secondary Schoolgirls. Indian Journal of Pediatrics. 2019 Jan;86(Suppl 1):34-41.
  131. Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI, et al. Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. Journal of Clinical Medicine. 2019;8(6):908.
  132. Vigil P, Lyon C, Flores B, et al. Ovulation, a sign of health. Linacre Q. 2017;84(4):343-355.
  133. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006 Nov;118(5):2245-50.
  134. Fehring RJ, Bouchard T, Meyers M. Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults. Linacre Q. 2018;85(2):167-177.
  135. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Human Reproduction. 2011 Aug;26(8):2028-35.
  136. Tu FF, Du H, Goldstein GP, Beaumont JL, et al. The influence of prior oral contraceptive use on risk of endometriosis is conditional on parity. Fertility and Sterility. 2014 Jun;101(6):1697-704.
  137. Sisk CL. Hormone-dependent adolescent organization of socio-sexual behaviors in mammals. Current Opinion in Neurobiology. 2016;38:63-68.
  138. Cahill, L. How does hormonal contraception affect the developing human adolescent brain? Current Opinion in Behavioral Sciences. 2018; 23:131–135.
  139. de Wit AE, Booij SH, Giltay EJ, et al. Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. JAMA Psychiatry. 2020 Jan 1;77(1):52-59.
  140. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018;13(3):e0194773.
  141. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016 Nov 1;73(11):1154-1162.
  142. Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European Journal of Contraception & Reproductive Health Care : the official journal of the European Society of Contraception. 2012 Apr;17(2):106-18.
  143. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. The American Journal of Psychiatry. 2018 Apr 1;175(4):336-342.
  144. Strifert K. The link between oral contraceptive use and prevalence in autism spectrum disorder. Medical Hypotheses. 2014 Dec;83(6):718-25.
  145. Casey PM, MacLaughlin KL, Faubion SS. Impact of Contraception on Female Sexual Function. Journal of Womens Health (Larchmt). 2017 Mar;26(3):207-213.
  146. Battaglia C, Morotti E, Persico N, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Journal of Sexual Medicine. 2014 Feb;11(2):471-80.
  147. Zheng J, Islam RM, Skiba, MA, et al. Associations between androgens and sexual function in premenopausal women: a cross-sectional study. The Lancet, Diabetes & Endocrinology. 2020; 8(8):693–702.
  148. Coelingh Bennink HJT, Zimmerman Y, Laan E, et al. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects. Contraception. 2017 Nov;96(5):322-329
  149. Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update. 2014 Jan;20(1):76-105.
  150. Hayes E, Gavrilidis E, Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophrenia Research and Treatment. 2012;2012:540273.
  151. Petersen N, Kilpatrick LA, Goharzad A, Cahill L. Oral contraceptive pill use and menstrual cycle phase are associated with altered resting state functional connectivity. NeuroImage. 2014 Apr;90:24-32
  152. Marecková K, Perrin JS, Nawaz Khan I, et al. Hormonal contraceptives, menstrual cycle and brain response to faces. Social Cognitive and Affective Neuroscience. 2012;9(2):191-200.
  153. Maged AM, Salah E, Kamel AM. et al. Effect of oral contraceptives on balance in women: A randomized controlled trial. Taiwanese Journal of Obstetrics & Gynecology. 2017 Aug;56(4):463-466.
  154. Scavello I, Maseroli E, Di Stasi V et al. Nomegestrol acetate/17beta-estradiol does not negatively alter the vascular resistance of clitoral arteries: a prospective, exploratory study. International Journal of Impotence Research. 2020 Mar;32(2):239-247.
  155. Battaglia C, Morotti E, Persico N, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Journal of Sexual Medicine. 2014 Feb;11(2):471-80.
  156. Basson R. Clinical practice. Sexual desire and arousal disorders in women. The New England Journal of Medicine. 2006 Apr 6;354(14):1497-506.
  157. Malmborg A, Brynte L, Falk G, et al. Sexual function changes attributed to hormonal contraception use – a qualitative study of women experiencing negative effects. European Journal of Contraception and Reproductive Health Care. 2020 Jun;25(3):169-175.
  158. de Castro Coelho F, Barros C. The Potential of Hormonal Contraception to Influence Female Sexuality. International Journal of Reproductive Medicine. 2019;2019:9701384.
  159. Malmborg A, Persson E, Brynhildsen J, et al. Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. European Journal of Contraception and Reproductive Health Care. 2016;21(2):158-67
  160. Wallwiener CW, Wallwiener LM, Seeger H, et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Archives of Gynecology and Obstetrics. 2015 Oct;292(4):883-90.
  161. Lev-Sagie A, Wertman O, Lavee Y, Granot M. Vestibular Anatomic Localization of Pain Sensitivity in Women with Insertional Dyspareunia: A Different Approach to Address the Variability of Painful Intercourse. Journal of Clinical Medicine. 2020;9(7):2023.
  162. Tayyeb M, Gupta V. Dyspareunia. [Updated 2020 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562159.
  163. M, Bogani G, Di Dedda MC, Braghiroli A, et al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2015 Aug;191:48-50.
  164. Champaneria R, D’Andrea RM, Latthe PM. Hormonal contraception and pelvic floor function: a systematic review. International Urogynecology Journal. 2016 May;27(5):709-22.
  165. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. Journal of Sexual Medicine 2014;11:2764–2771.
  166. Gardella B, Porru D, Nappi RE, et al. Interstitial cystitis is associated with vulvodynia and sexual dysfunction–a case-control study. Journal of Sexual Medicine. 2011 Jun;8(6):1726-34.
  167. Bouchard C, Brisson J, Fortier M, et al. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. American Journal of Epidemiologyl. 2002 Aug 1;156(3):254-61.
  168. Harlow BL, Vitonis AF, Stewart EG. Influence of oral contraceptive use on the risk of adult-onset vulvodynia. The Journal of Reproductive Medicine. 2008 Feb;53(2):102-10.
  169. Battaglia C, Morotti E, Persico N, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Journal of Sexual Medicine. 2014 Feb;11(2):471-80.
  170. Max Horkheimer. Die Sehnsucht nach dem ganz Anderen: Max Horkheimer im Interview mit Helmut Gumnior. Hamburg: Furche Verlag. 1970, s. 73-76: „Die Pille müssen wir mit dem Tod der erotischen Liebe bezahlen…Ich halte es jedoch für meine Pflicht, den Men-schen klarzumachen, daß wir für diesen Fortschritt einen Preis bezahlen müssen und dieser Preis ist die Beschleunigung des Verlustes der Sehnsucht, letztlich der Tod der Liebe“.
  171. Wisman A, Shrira I. Sexual Chemosignals: Evidence that Men Process Olfactory Signals of Women’s Sexual Arousal. Archives of Sexual Behavior. 2020;49(5):1505-1516.
  172. Tarumi W, Shinohara K. Women’s body odour during the ovulatory phase modulates testosterone and cortisol levels in men. PLoS One. 2020 Mar 31;15(3):e0230838.
  173. Gildersleeve KA, Haselton MG, Larson CM, Pillsworth EG. Body odor attractiveness as a cue of impending ovulation in women: evidence from a study using hormone-confirmed ovulation. Hormones and Behavior. 2012 Feb;61(2):157-66.
  174. Cerda-Molina AL, Hernández-López L, de la O CE, Chavira-Ramírez R, et al. Men’s Salivary Testosterone and Cortisol Levels, and in Sexual Desire after Smelling Female Axillary and Vulvar Scents. Frontiers in Endocrinology. 2013 Oct 28;4:159.
  175. van Anders SM. Testosterone and sexual desire in healthy women and men. Archives of Sexual Behavior. 2012 Dec;41(6):1471-84.
  176. Cerda-Molina AL, Hernández-López L, de la O CE, Chavira-Ramírez R, et al. Men’s Salivary Testosterone and Cortisol Levels, and in Sexual Desire after Smelling Female Axillary and Vulvar Scents. Frontiers in Endocrinology. 2013 Oct 28;4:159.
  177. Miller SL, Maner JK. Scent of a woman: men’s testosterone responses to olfactory ovulation cues. Psychological Science. 2010 Feb;21(2):276-83.
  178. Kuukasjärvi SCJ, Eriksson P, Koskela E, et al. Attractiveness of women’s body odors over the menstrual cycle: the role of oral contraceptives and receiver sex, Behavioral Ecology, 2004;15(4): 579–584.
  179. Renfro KJ, Hoffmann H. The relationship between oral contraceptive use and sensitivity to olfactory stimuli. Hormones and Behavior. 2013 Mar;63(3):491-6.
  180. Marcinkowska UM, Holzleitner IJ. Stability of women’s facial shape throughout the menstrual cycle. Proceedings. Biological sciences / The Royal Society. 2020 Apr 8;287(1924):20192910.
  181. Catena TM, Simmons ZL, Roney JR. Do women’s faces become more attractive near ovulation? Hormones and Behavior. 2019 Sep;115:104560.
  182. Roberts SC, Havlicek J, Flegr J, et al. Female facial attractiveness increases during the fertile phase of the menstrual cycle. Proceedings. Biological sciences / The Royal Society. 2004 Aug 7;271 Suppl 5(Suppl 5):S270-2
  183. Feinberg DR, DeBruine LM, Jones BC. Correlated preferences for men’s facial and vocal masculinity. Evolution and Human Behavior. 2008; 29 (4):233-241.
  184. Little AC, Burriss RP, Petrie M, et al. Oral contraceptive use in women changes preferences for male facial masculinity and is associated with partner facial masculinity. Psychoneuroendocrinology. 2013 Sep;38(9):1777-85.
  185. Alvergne A, Lummaa V. Does the contraceptive pill alter mate choice in humans? Trends in Ecology and Evolution. 2010 Mar;25(3):171-9.
  186. Jones BC, DeBruine LM, Perrett DI, et al. Effects of menstrual cycle phase on face preferences. Archives of Sexual Behavior. 2008 Feb;37(1):78-84.
  187. Havlicek J, Roberts SC. MHC-correlated mate choice in humans: a review. Psychoneuroendocrinology. 2009 May;34(4):497-512.
  188. Roberts SC, Klapilová K, Little AC, et al. Relationship satisfaction and outcome in women who meet their partner while using oral contraception. Proceedings. Biological sciences/The Royal Society. 2012 Apr 7;279(1732):1430-6.
  189. Scheele D, Plota J, Stoffel-Wagner B, et al. Hormonal contraceptives suppress oxytocin-induced brain reward responses to the partner’s face. Social Cognitive and Affective Neuroscience. 2016;11(5):767-774.
  190. Encyclopaedia Britannica. Androgen. https://www.britannica.com/science/androgen. Accessed 2 Feb 2021.
  191. Gollnick HP, Zouboulis CC. Not all acne is acne vulgaris. Deutsches Ärzteblatt International. 2014 Apr 25;111(17):301-12.
  192. Leidenberger F, Strowitzki T, Ortmann O. Klinische Endokrinologie für Frauenärzte, 4th ed. Heidelberg: Springer Medizin Verlag, 2009.
  193. Оshyvalova ОО, Ziukov OL, Gurianov VG. Prognostic model of skin cancer risk assessment. Wiadomości Lekarskie. 2019;72(5 cz 1):817-822.
  194. Kuklinski LF, Zens MS, Perry AE, et al. Sex hormones and the risk of keratinocyte cancers among women in the United States: a population-based case-control study. International Journal of Cancer. 2016 Jul;139(2):300-309.
  195. Beheshtiroy A. Hajmanoochehri F. Epidemiological Study of Non-Melanoma Skin Cancers Qazvin Province, Iran. Biotechnology and Health Sciences. 2014 November; 1(3): e25362.
  196. Sun Q, Sun H, Cong L, Zheng Y, et al. Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis. Clinical Epidemiology. 2020;12:1183-1203.
  197. Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer. 2020 Jun 15;146(12):3267-3280.
  198. Cervenka I, Mahamat-Saleh Y, Savoye I, et al. Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study. International Journal of Cancer. 2018 Nov 15;143(10):2390-2399
  199. Sun Q, Sun H, Cong L, Zheng Y, et al. Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis. Clinical epidemiology. 2020;12:1183-1203.
  200. Centers for Disease Control and Prevention. Systemic Lupus Erythematosus. https://www.cdc.gov/lupus/facts/detailed.html. Accessed 2 December 2020.
  201. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis and Rheumatism. 2007 Apr;56(4):1251-62.
  202. Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis and Rheumatism. 2009 Apr 15;61(4):476-81.
  203. Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis and Rheumatism. 1997 May;40(5):804-8.
  204. Tosti A, Pazzaglia M. Drug reactions affecting hair: diagnosis. Dermatologic Clinics. 2007 Apr;25(2):223-31, vii.
  205. Leidenberger F, Strowitzki T, Ortmann O. Klinische Endokrinologie für Frauenärzte, 4th ed. Heidelberg: Springer Medizin Verlag, 2009. s. 278.
  206. Polakova K. Spolupráca gynekológa a dermatológa pri užívaní kombinovanej hormonálnej antikoncepcie s antiandrogénovým účinkom. Dermatológia pre Prax. 2010, 4(3): 113–115.
  207. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. Journal of the American Academy of Dermatology. 2011 Oct;65(4):689-697.
  208. Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009 Nov;23(11):1254-62.
  209. Leidenberger F, Strowitzki T, Ortmann O. Klinische Endokrinologie für Frauenärzte, 4th ed. Heidelberg: Springer Medizin Verlag, 2009. s .278.
  210. El-Darouti MA., Al-Ali FM. Livedo Reticularis Associated with Ulceration. In: Challenging Cases in Dermatology Volume 2. Springer, Cham. 2019. https://doi.org/10.1007/978-3-030-21855-3_9.
  211. Leidenberger F, Strowitzki T, Ortmann O. Klinische Endokrinologie für Frauenärzte, 4th ed. Heidelberg: Springer Medizin Verlag, 2009. s. 278.
  212. Deharo C, Berbis P, Privat Y. Complications dermatologiques des contraceptifs oraux [Dermatological complications caused by oral contraceptives]. Fertilité, Contraception, Sexualité. 1988 Apr;16(4):299-304.
  213. Asherson RA, Harris EN, Hughes GR, Farquharson RG. Complications of oral contraceptives and antiphospholipid antibodies: reply to the letter by Bruneau et al. Arthritis and Rheumatism. 1988 Apr;31(4):575-6.
  214. Andrews C, Mathew J. The morning after rash: Erythema nodosum due to emergency contraception. Journal of Case Reports and Images in Medicine. 2018;4:100045Z09CA2018.
  215. Molina-Ruiz AM, Requena L. Erythema nodosum. Medicina Clínica (English Edition), 2016; 147(2): 81–86.
  216. Borroni G, Torti S, D’Ospina RM, Pezzini C. Drug-induced panniculitides. Giornale Italiano di Dermatologia e Venereologia : Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia. 2014 Apr;149(2):263-70.
  217. Vessey MP, Painter R, Powell J. Skin disorders in relation to oral contraception and other factors, including age, social class, smoking and body mass index. Findings in a large cohort study. The British Journal of Dermatology.2000 Oct;143(4):815-20.
  218. Adeel M, Song X, Wang Y, et al. Environmental impact of estrogens on human, animal and plant life: A critical review. Environment International. 2017 Feb;99:107-119.
  219. Ying GG, Kookana RS, Dillon P. Sorption and degradation of selected five endocrine disrupting chemicals in aquifer material. Water Research. 2003 Sep;37(15):3785-91.
  220. Margel D, Fleshner NE. Oral contraceptive use is associated with prostate cancer: an ecological study. BMJ Open. 2011 Nov 14;1(2):e000311.
  221. Joffe M; Department of Epidemiology and Public Health, Imperial College School of Medicine, London, UK. m.joffe@ic.ac.uk. Are problems with male reproductive health caused by endocrine disruption? Occupational and Environmental Medicine. 2001 Apr;58(4):281-7; quiz 287-8, 260.
  222. Svensson J, Mustafa A, Fick J, et al. Developmental exposure to progestins causes male bias and precocious puberty in zebrafish (Danio rerio). Aquatic Toxicology. 2016 Aug;177:316-23.
  223. Kvarnryd M, Grabic R, Brandt I, et al. Early life progestin exposure causes arrested oocyte development, oviductal agenesis and sterility in adult Xenopus tropicalis frogs. Aquatic Toxicology. 2011;103(1-2):18-24.
  224. Claudia Lorenz, Valeska Contardo-Jara, Achim Trubiroha, et al. The synthetic gestagen Levonorgestrel disrupts sexual development in Xenopus laevis by affecting gene expression of pituitary gonadotropins and gonadal steroidogenic enzymes. Toxicological Sciences, 2011 Dec; 124 (2): Pages 311–9.
  225. Steinbach C, Císař P, Šauer P, et al. Synthetic progestin etonogestrel negatively affects mating behavior and reproduction in Endler’s guppies (Poecilia wingei). Science of The Total Environment. 2019 May 1;663:206-215.
  226. Howard PE, Bjorling DE. The intersexual animal. Associated problems. Problems in Veterinary Medicine. 1989 Jan-Mar;1(1):74-84.
  227. Jackson LM, Felgenhauer BE, Klerks PL. Feminization, altered gonadal development, and liver damage in least killifish (Heterandria formosa) exposed to sublethal concentrations of 17α-ethinylestradiol. Ecotoxicology and Environmental Safety. 2019 Apr;170:331-337.
  228. Jobling, S, Owen R. Ethinyl estradiol: bitter pill for the precautionary principle. Late Lessons from Early Warnings: Science, Precaution, Innovation. 2013. 311-339.
  229. Cosme MM, Lister AL, Van Der Kraak G. Inhibition of spawning in zebrafish (Danio rerio): Adverse outcome pathways of quinacrine and ethinylestradiol. General and Comparative Endocrinology.2015 Aug 1;219:89-101.
  230. Young BJ, Lopez GC, Cristos DS, et al. Carriquiriborde, Intersex and liver alterations induced by long-term sublethal exposure to 17alpha-ethinylestradiol in adult male Cnesterodon decemmaculatus (Pisces: Poeciliidae). Environmental Toxicology and Chemistry. 2017; 36(7):1738–1745.
  231. Sridevi P, Chaitanya RK, Prathibha Y, et al. Early exposure of 17α-ethynylestradiol and diethylstilbestrol induces morphological changes and alters ovarian steroidogenic pathway enzyme gene expression in catfish, Clarias gariepinus. Environmenta Toxicology. 2015 Apr;30(4):439-51. d
  232. Saaristo M, Johnstone CP, Xu K, et al.The endocrine disruptor, 17α-ethinyl estradiol, alters male mate choice in a freshwater fish. Aquatic Toxicology. 2019 Mar;208:118-125.
  233. Kidd KA, Blanchfield PJ, Mills KH, et al. Collapse of a fish population after exposure to a synthetic estrogen. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8897-901.
  234. Länge R, Hutchinson TH, Croudace CP, et al. Effects of the synthetic estrogen 17 alpha-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas). Environmental Toxicology and Chemistry / SETAC. Chem. 2001 Jun;20(6):1216-27.
  235. Meerwijk EL, Sevelius JM. Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples. American Journal of Public Health. 2017;107(2):e1-e8.
  236. Arcelus J, Bouman WP, Van Den Noortgate. Systematic review and meta-analysis of prevalence studies in transsexualism. European Psychiatry : the Journal of the Association of European Psychiatrists. 2015 Sep;30(6):807-15.
  237. Meerwijk EL, Sevelius JM. Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples. American Journal of Public Health. 2017;107(2):e1-e8.
  238. Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets. The Journal of Sexual Medicine. 2018 Apr;15(4):582-590.
  239. Lee PA, Houk CP, Ahmed SF, Hughes IA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006 Aug;118(2):e488-500.
  240. World Health Organization (WHO) Gender and Genetics: Genetic Components of Sex and Gender. https://www.who.int/genomics/gender/en/. Accessed 2 Feb 2021.
  241. Ahmed SF, Dobbie R, Finlayson AR, et al. Prevalence of hypospadias and other genital anomalies among singleton births, 1988-1997, in Scotland. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2004 Mar;89(2):F149-51.
  242. Gaspari L, Paris F, Jandel C, et al. Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: a nested case–control study. Human Reproduction. 2011;26(11):3155–62.
  243. Luoto S, Krams I, Rantala MJ. A Life History Approach to the Female Sexual Orientation Spectrum: Evolution, Development, Causal Mechanisms, and Health. Archives of Sexual Behavior. 2019 Jul;48(5):1273-1308.
  244. Rice WR, Friberg U, Gavrilets S. Homosexuality as a consequence of epigenetically canalized sexual development. The Quarterly Review of Biology. 2012 Dec;87(4):343-68.
  245. Svechnikov K, Stukenborg JB, Savchuck I, et al. Similar causes of various reproductive disorders in early life. Asian Journal of Andrology. 2014;16(1):50-59.
  246. Baggio, AM. Eros, sila lásky. 1. vyd. Bratislava : Nové mesto, 1993. s. 40.
  247. Baggio, AM. Eros, sila lásky. 1. vyd. Bratislava : Nové mesto, 1993. s. 22.
  248. Sprecher S., O’Sullivan LF, Drouin M et al. The Significance of Sexual Debut in Women’s Lives. Current Sexual Health Reports 11, 2019. 265–273.
  249. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009 Apr;18(4):1060-9.
  250. Olesen TB, Jensen KE, Nygård M, et al. Young age at first intercourse and risk-taking behaviours—a study of nearly 65000 women in four Nordic countries. European Journal of Public Health. 2012 Apr;22(2):220–224.
  251. Greenberg J, Magder L, Aral S. Age at first coitus. A marker for risky sexual behavior in women. Sexually Transmitted Diseases. 1992 Nov-Dec;19(6):331-4.
  252. de Wit AE, Booij SH, Giltay EJ, et al. Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. JAMA Psychiatry. 2020 Jan 1;77(1):52-59.
  253. Fehring RJ, Bouchard T, Meyers M. Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults. Linacre Q. 2018;85(2):167-177
  254. Weitzman A, Barber J, Kusunoki Y. Sexual Concurrency and Contraceptive Use Among Young Adult Women. Demography. 2019;56(2):549-572.
  255. Little AC, Jones BC, Penton-Voak IS, et al. Partnership status and the temporal context of relationships influence human female preferences for sexual dimorphism in male face shape. Proceedings. Biological Sciences /The Royal Society. 2002;269(1496):1095-1100.
  256. Rodrigues, D., Lopes, D. Sociosexuality, Commitment, and Sexual Desire for an Attractive Person. Archives of Sexual Behavior.2017. 46: 775–788 .
  257. Guillermo CJ, Manlove HA, Gray PB, et al. Female social and sexual interest across the menstrual cycle: the roles of pain, sleep and hormones. BMC Womens Health. 2010;10:19.
  258. Yoeli E, Becker G, Cohen L, et al. Does Birth-Control Promote Promiscuity or Improve Health Care? Evidence from Sexually Transmitted Diseases. https://www.researchgate.net/profile/Eric_Sun6/publication/228808325_Does_Birth_Control_Promote_Promiscuity_or_Improve_Health_Care_Evidence_from_Sexually_Transmitted_Diseases/links/00b495266210e6691a000000/Does-Birth-Control-Promote-Promiscuity-or-Improve-Health-Care-Evidence-from-Sexually-Transmitted-Diseases.pdf?origin=publication_detail. Accessed 11 Dec 2020.
  259. Murphy K, Irvin SC, Herold BC. Research Gaps in Defining the Biological Link between HIV Risk and Hormonal Contraception. American Journal of Reproductive Immunology. 2014;72(2):228-235.
  260. Johannesson U, Blomgren B, Hilliges M et al. The vulval vestibular mucosa-morphological effects of oral contraceptives and menstrual cycle. The British Journal of Dermatology. 2007 Sep;157(3):487-93.
  261. Haddad LB, Wall KM, Kilembe W, et al. Bacterial vaginosis modifies the association between hormonal contraception and HIV acquisition. AIDS. 2018 Mar 13;32(5):595-604.
  262. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007 Aug 20;21(13):1771-7.
  263. Lavreys L, Baeten JM, Martin HL Jr, et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS. 2004 Mar 5;18(4):695-7.
  264. Achilles SL, Hillier SL. The Complexity of Contraceptives: Understanding Their Impact on Genital Immune Cells and Vaginal Microbiota. AIDS. 2013;27(0 1):S5-15.
  265. World Health Organization, Sexually transmitted infections (STIs), (December, 2015), [cit. 2016-04-04]. http://www.who.int/mediacentre/factsheets/fs110/en/.
  266. ICO/IARC HPV Information Centre. 2019. https://hpvcentre.net/statistics/ reports/XWX.pdf. Accessed 23 Dec 2020.
  267. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017 Aug 15;141(4):664-670.
  268. Winer RL, Hughes JP, Feng Q, et al. Incident Detection of High-Risk Human Papillomavirus Infections in a Cohort of High-Risk Women Aged 25-65 Years. The Journal of Infectious Diseases. 2016;214(5):665-675.
  269. Marks M, Gravitt PE, Gupta SB, et al. The association of hormonal contraceptive use and HPV prevalence. International Journal of Cancer. 2011 Jun 15;128(12):2962-70.
  270. Baudu A, Prétet JL, Riethmuller D, et al. Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15-23 years. Journal of Epidemiology and Global Health. 2014 Mar;4(1):35-43.
  271. Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K. Prevalence and risk factors of HPV infection among women from various provinces of the world. Archives of Gynecology and Obstetrics. 2012 Mar;285(3):771-7.
  272. Stensen S, Kjaer SK, Jensen SM, et al. Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study. International Journal of Cancer. 2016 Jan 15;138(2):361-8.
  273. Smith JS, Herrero R, Muñoz N, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sexually Transmitted Diseases. 2001 Apr;28(4):187-94.
  274. Cherpes TL, Melan MA, Kant JA, et al. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2005;40:1422–1428.
  275. World Health Organization, Sexually transmitted infections (STIs), (December, 2015), [cit. 2016-04-04]. http://www.who.int/mediacentre/factsheets/fs110/en/.
  276. Orozco-Hoyos N, Baena A, Montoya-Ruiz C, et al. Prevalence of Chlamydia trachomatis in an asymptomatic female population attending cervical cytology services of three healthcare centers in Medellín, Colombia. Prevalencia de Chlamydia trachomatis en la población femenina asintomática atendida en los servicios de citología cervical de tres instituciones prestadoras de servicios de salud en Medellín, Colombia. Biomedica. 2020;40(3):534-545.
  277. Brahmbhatt H, Musoke R, Makumbi F, et al. Trichomonas vaginalis Incidence Associated with Hormonal Contraceptive Use and HIV Infection among Women in Rakai, Uganda. Journal of Sexually Transmitted Diseases. 2014; Vol. 2014: 1–10.
  278. Borgdorff H, Verwijs MC, Wit FW, et al. The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers. Sexually Transmitted Diseases. 2015 Mar;42(3):143-52.
  279. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception. 2006 Feb;73(2):154-65.
  280. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. American Journal of Obstetrics and Gynecology. 2001 Aug;185(2):380-5.
  281. Hiltunen-Back E, Haikala O, Kautiainen H, et al. A nationwide sentinel clinic survey of chlamydia trachomatis infection in Finland. Sexually Transmitted Diseases. 2001 May;28(5):252-8.
  282. Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the risk of chlamydial and gonococcal infections. American Journal of Obstetrics and Gynecology. 1989 Feb;160(2):396-402.
  283. Borgdorff H, Verwijs MC, Wit FW, et al. The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers. Sexually Transmitted Diseases. 2015 Mar;42(3):143-52.
  284. WHO, Sexually transmitted infections. 2019. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis). Accessed 28 Dec 2020.
  285. Guttmacher Policy Review. Contraceptive Use Is Key to Reducing Abortion Worldwide. https://www.guttmacher.org/gpr/2003/10/contraceptive-use-key-reducing-abortion-worldwide. Accessed 28 Dec 2020.
  286. Fehring RJ, Bouchard T, Meyers M. Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults. Linacre Q. 2018;85(2):167-177.
  287. Falah-Hassani K. Changes in Sexual Behavior and Hormonal Contraceptives Use Among Finnish Adolescents. Academic dissertation. University of Tampere, School of Public Health Finland. 2010https://trepo.tuni.fi/bitstream/handle/10024/66630/978-951-44-8138-3.pdf?sequence=1&isAllowed=y. Accessed 29 dec 2020.
  288. Dinger JC et al. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. America Journal of Obstetrics and Gynecology. 2009 Sep; 201:263.e1.
  289. Hillard, PJA. Oral contraception noncompliance: The extent of the problem. Advances in Contraception. 1992; 8(S1): 13–20.
  290. Study commissioned by the German Federal Centre for Health Education. 2016. Forschung und Praxis der Sexualaufklärung und Familienplanung—Band 38: frauen leben 3—Familienplanung im Lebenslauf von Frauen—Schwerpunkt: Ungewollte Schwangerschaften. http://www.forschung.sexualaufklaerung.de/fileadmin//fileadmin-forschung/pdf/Frauenleben3_Langfassung_Onlineversion. compressed.pdf. Accessed May 2016.
  291. Singh S, Darroch JE, Ashford LS, et al. The Costs and Benefits of Investing in Sexual and Reproductive Health 2014, New York: Guttmacher Institute. 2014. https://www.guttmacher.org/sites/default/files/report_pdf /addingitup2014.pdf. Accessed 12 Dec 2019.
  292. Guttmacher Institute. 2020.Unintended pregnancy and abortion rates, by region, 2015–2020. https://www.guttmacher.org/fact-sheet/induced-abortion-worldwide. Accessed 28 Dec 2020.
  293. Jones RK. Reported contraceptive use in the month of becoming pregnant among U.S. abortion patients in 2000 and 2014. Contraception. 2018;97(4):309-312.
  294. Socialstyrelsen. Abortstatistik. 2017. https://www.socialstyrelsen.se/ publikationer2018/2018-5-17. Accesed 12 Jan 2021.
  295. Jones R, Jerman J, Ingerick M. Which Abortion Patients Have Had a Prior Abortion? Findings from the 2014 U.S. Abortion Patient Survey. Journal of Women’s Health. 2018;27(1):58-63.
  296. United Kingdom Government. Abortion Statistics, England and Wales: 2017. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/763174/2017-abortion-statistics-for-england-and-wales-revised.pdf. Accessed 12 Jan 2021.
  297. Jones R, Jerman J, Ingerick M. Which Abortion Patients Have Had a Prior Abortion? Findings from the 2014 U.S. Abortion Patient Survey. Journal of Women’s Health. 2018;27(1):58-63.
  298. Fehring RJ, Bouchard T, Meyers M. Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults. Linacre Q. 2018;85(2):167-177.
  299. García-Enguídanos A, Martínez D, Calle ME, et al. Long-term use of oral contraceptives increases the risk of miscarriage. Fertility and Sterility. 2005;83(6):1864-1866.
  300. Hahn KA, Hatch EE, Rothman KJ, et al. History of oral contraceptive use and risk of spontaneous abortion. Annals of Epidemiology. 2015;25(12):936-41.e1.
  301. Harlap S, Shiono PH, Ramcharan S. Spontaneous foetal losses in women using different contraceptives around the time of conception. International Journal of Epidemiology. 1980 Mar;9(1):49-56.
  302. Li C, Wu YT, Zhu Q, et al. TRPV4 is involved in levonorgestrel-induced reduction in oviduct ciliary beating. The Journal of Pathology. 2019;248(1):77–87.
  303. Taubert, HD, Kuhl H. Kontrazeption mit Hormonen. Stuttgart: Georg Thieme Verlag, 1995. s. 131.
  304. Taubert, HD, Kuhl H. Kontrazeption mit Hormonen. Stuttgart: Georg Thieme Verlag, 1995. s. 133-134.
  305. United Nations. Contraceptive Use by Method 2019. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf. Accesed 26 dec 2020.
  306. Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability. Therapeutics and Clinical Risk Management. 2009;5(3):561-574.
  307. Aristoteles. Etika Nikomachova. 3. vyd. Praha : Petr Rezek, 2009. 1129a, 1129b. s. 112.
  308. Akvinský T. Theologická summa I, q. 20, 1 ad 3. Olomouc : Krystal, 1938.
  309. Jankélévitch V. Le sérieux de l’ intention : Traité des vertus I. Paris : Flammarion, 1983. s. 8: „Alors même que la voracité de l´égo ne śexercerait pas aux dépens du bonheur des autres, l´égoïsme serait encore détestable“.
  310. Wallwiener CW, Wallwiener LM, Seeger H, et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Archives of Gynecology and Obstetrics. 2015 Oct;292(4):883-90.
  311. Malmborg A, Brynte L, Falk G, et al. Sexual function changes attributed to hormonal contraception use – a qualitative study of women experiencing negative effects. European Journal of Contraception and Reproductive Health Care. 2020 Jun;25(3):169-175.
  312. de Castro Coelho F, Barros C. The Potential of Hormonal Contraception to Influence Female Sexuality. International Journal of Reproductive Medicine. 2019;2019:9701384.
  313. Battaglia C, Morotti E, Persico N, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Journal of Sexual Medicine. 2014 Feb;11(2):471-80.
  314. Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. Journal of Sexual Medicine. 2014 Feb;11(2):462-70.
  315. Sokol J. Filosofická antropologie. 2. vyd. Praha : Portál, 2008. s. 47.
  316. Weiss P. a kol. Sexuologie. 1. vyd. Praha : Grada Publishing, 2010. s. 90.
  317. Shakerian A, Nazari AM, Masoomi M. Inspecting the Relationship between Sexual Satisfaction and Marital Problems of Divorce-asking Women in Sanandaj City Family Courts. Procedia – Social and Behavioral Sciences 114 ( 2014 ) 327 – 333.
  318. Davidson MR. Marriage and mental illness. The Wiley-Blackwell encyclopedia of family studies. Editors: C.L. Shehan. New York: John Wiley & Sons (UK). 2016. ISBN: 9780470658451.
  319. WORDBANK. Between 1960 and 2012, the world average fertility rate halved to 2.5 births per woman. July 2014. https://blogs.worldbank.org/opendata/between 960-and012-world-average-fertility-rate-halved5-births-woman. Accessed 14 Jan 2021.
  320. Leridon H. Demographic effects of the introduction of steroid contraception in developed countries. Human Reproduction Update. 2006 Sep-Oct;12(5):603-16.
  321. Benagiano G, Testa G, Cocuzzi L. Significato del controllo della fertilità in un mondo integrato [The meaning of fertility control in an integrated world]. Minerva Ginecologica. 2004 Jun;56(3):271-81.
  322. Bailey M. More Power to the Pill: The Impact of Contraceptive Freedom on Women’s Life Cycle Labor Supply. Quarterly Journal of Economics. 2006; (121):289-320.
  323. Bailey M.. “”Momma’s Got the Pill”: How Anthony Comstock and Griswold v. Connecticut Shaped US Childbearing.” American Economic Review. 2010. 100 (1): 98-129.
  324. Guldi M. Fertility effects of abortion and birth control pill access for minors. Demography. 2008;45(4):817-827.
  325. Weiss P. a kol. Sexuologie. 1. vyd. Praha : Grada Publishing, 2010. s. 90.
  326. Letourneau JM, Cakmak H, Quinn M, Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield. Journal of Assisted Reproduction and Genetics. 2017;34(9):1137-1144.
  327. Birch Petersen K, Hvidman HW, Forman JL. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Human Reproduction. 2015 Oct;30(10):2364-75.
  328. Kallio S, P J, FRuokonen A, Vaskivuo T, et al. AMH levels decrease in women using combined contraception independently of administration route. Fertility and Sterility. 2013;99:1305–1310.
  329. Shakerian A, Nazari AM, Masoomi M. Inspecting the Relationship between Sexual Satisfaction and Marital Problems of Divorce-asking Women in Sanandaj City Family Courts. Procedia – Social and Behavioral Sciences 114 ( 2014 ) 327 – 333.
  330. Wallwiener CW, Wallwiener LM, Seeger H, et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Archives of Gynecology and Obstetrics. 2015 Oct;292(4):883-90.
  331. Malmborg A, Brynte L, Falk G, et al. Sexual function changes attributed to hormonal contraception use – a qualitative study of women experiencing negative effects. European Journal of Contraception and Reproductive Health Care. 2020 Jun;25(3):169-175.
  332. de Castro Coelho F, Barros C. The Potential of Hormonal Contraception to Influence Female Sexuality. International Journal of Reproductive Medicine. 2019;2019:9701384.
  333. Battaglia C, Morotti E, Persico N, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Journal of Sexual Medicine. 2014 Feb;11(2):471-80.
  334. Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. Journal of Sexual Medicine. 2014 Feb;11(2):462-70.
  335. Lev-Sagie A, Wertman O, Lavee Y, Granot M. Vestibular Anatomic Localization of Pain Sensitivity in Women with Insertional Dyspareunia: A Different Approach to Address the Variability of Painful Intercourse. Journal of Clinical Medicine. 2020;9(7):2023.
  336. Tayyeb M, Gupta V. Dyspareunia. [Updated 2020 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562159
  337. Serati M, Bogani G, Di Dedda MC, et al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2015 Aug;191:48-50.
  338. Champaneria R, D’Andrea RM, Latthe PM. Hormonal contraception and pelvic floor function: a systematic review. International Urogynecology Journal. 2016 May;27(5):709-22.
  339. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. Journal of Sexual Medicine 2014;11:2764–2771.
  340. Breslau J, Miller E, Jin R, et al. A multinational study of mental disorders, marriage, and divorce. Acta Psychiatrica Scandinavica. 2011;124(6):474-486.
  341. Gabriel B, Beach SRH, Bodenmann G.  Depression, Marital Satisfaction and Communication in Couples: Investigating Gender Differences. Behavior Therapy. 2010; 41(3): 306–316.
  342. Moyá J, Cano-Prous A, Fernández A at al. The impact a first episode of major depression has on marital dissatisfaction: Is remission associated with improvement in dissatisfaction?. European Journal of Psychiatry. 2010;24(1).
  343. Pruchno R, Wilson-Genderson M, Cartwright FP. Depressive symptoms and marital satisfaction in the context of chronic disease: a longitudinal dyadic analysis. JFP. 2009;23(4):573-584.
  344. Gabriel B, Beach SR, Bodenmann G. Depression, marital satisfaction and communication in couples: investigating gender differences. Behavior Therapy. 2010 Sep;41(3):306-16.
  345. Weiss P. a kol. Sexuologie. 1. vyd. Praha : Grada Publishing, 2010. s. 424
  346. Fruzzetti F, Fidecicchi T. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clinical Drug Investigation. 2020 Dec;40(12):1097-1106.
  347. Lewis CA, Kimmig AS, Zsido RG, Jank A, Derntl B, Sacher J. Effects of Hormonal Contraceptives on Mood: A Focus on Emotion Recognition and Reactivity, Reward Processing, and Stress Response. Current Psychiatry Reports. 2019;21(11):115.
  348. Gingnell M, Engman J, Frick A. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill–a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. Psychoneuroendocrinology. 2013 Jul;38(7):1133-44.
  349. Wiréhn AB, Foldemo A, Josefsson A, Lindberg M. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. European Journal of Contraception and Reproductive Health Care. 2010 Feb;15(1):41-7.
  350. Young EA, Kornstein SG, Harvey AT, et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology. 2007;32(7):843-853.
  351. de Wit AE, Booij SH, Giltay EJ, et al. Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. JAMA Psychiatry. 2020 Jan 1;77(1):52-59.
  352. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018;13(3):e0194773.
  353. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016 Nov 1;73(11):1154-1162.
  354. Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European Journal of Contraception & Reproductive Health Care : the official journal of the European Society of Contraception. 2012 Apr;17(2):106-18.
  355. Statista. https://www.statista.com/statistics/325210/us-divorce-rate-among-women/. Accessed 23 Oct 2020.
  356. Fehring RJ. The influence of contraception, abortion, and natural family planning on divorce rates as found in the 2006-2010 National Survey of Family Growth. Linacre Q. 2015;82(3):273-282.
  357. Marcén M. Divorce and the birth control pill. Universidad de Zaragoza. Munich Personal RePEc Archive. 2012. https://mpra.ub.uni-muenchen.de/35955/1/marcen_150112_divorce_pill_final_version.pdf. Accessed 7 Jan 2020.
  358. International Consortium for Emergency Contraception (ICEC), International Federation of Gynecology & Obstetrics (FIGO). Statement on Mechanism of Action (October 2008). How do Levonorgestrel-only emergency contraceptive pills (LNG ECPs) work to prevent pregnancy? http://www.thaidrugwatch.org/blog/wp-content/uploads/2013/12/ICEC2008Oct-HowDoECPspreventpregnancy.pdf. Accessed 31 March 2021.
  359. Peck R, Rella W, Tudela J, et al. Does levonorgestrel emergency contraceptive have a post-fertilization effect? A review of its mechanism of action. Linacre Q. 2016;83(1):35–51.
  360. Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertility and Sterility. 2010;93(6):2035–2041.
  361. Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 2012 Nov;31(6):556-69
  362. Kahlenborn C, Peck R, Severs WB. Mechanism of action of levonorgestrel emergency contraception. Linacre Q. 2015 Feb;82(1):18-33.
  363. Li HW, Liao SB, Yeung WS, et al. Ulipristal acetate resembles mifepristone in modulating human fallopian tube function. Human Reproduction. 2014 Oct 10;29(10):2156-62.
  364. Yuan J, Zhao W, Yan M, et al. Ulipristal Acetate Antagonizes the Inhibitory Effect of Progesterone on Ciliary Beat Frequency and Upregulates Steroid Receptor Expression Levels in Human Fallopian Tubes. Reproductive Sciences. 2015 Dec;22(12):1516-23.
  365. Li C, Wu YT, Zhu Q, et al. TRPV4 is involved in levonorgestrel-induced reduction in oviduct ciliary beating. The Journal of Pathology. 2019;248(1):77–87.
  366. Lira-Albarrán S, Durand M, Larrea-Schiavon MF, et al. Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle. Molecular and Cellular Endocrinology. 2017 May 15;447:1-11.
  367. Levy DP, Jager M, Kapp N, et al. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. Contraception. 2014 May;89(5):431-3.
  368. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010 Feb 13;375(9714):555-62.
  369. Tydén T, Aneblom G, von Essen L, et al. Trots lättillgängliga akut-p-piller sjunker inte antalet aborter. Studier av kvinnors kunskaper, attityder och erfarenheter av metoden [No reduced number of abortions despite easily available emergency contraceptive pills. Studies of women’s knowledge, attitudes and experience of the method]. Lakartidningen. 2002 Nov 21;99(47):4730-2, 4735. Swedish.
  370. Department of Health. Abortion statistics, England and Wales. 2017. https://www.gov.uk/government/ uploads/system/uploads/attachment_data/file/319460/Abortion_Statistics__England_and_Wales_2017.pdf. Accessed 30 April 2020.
  371. Deng Y, Xu H, Zeng X. Induced abortion and breast cancer: An updated meta-analysis. Medicine (Baltimore). 2018;97(3):e9613.
  372. Carlé A, Knudsen N, Jørgensen T, et al. Previous Live Births and Induced Abortions May Precede Later Development of Graves’ Hyperthyroidism. European Thyroid Journal. 2019;8(2):70–78.
  373. Alzheimer’s Association. Pregnancy and reproductive history may impact dementia risk, study suggests: Plus, the move to re-think the impact of hormone therapy on cognition. https://www.alz.org/aaic/downloads2018/Mon-am-briefing-women-dementia-risk.pdf. Accessed 31 Jan 2021.
  374. Ou SX, Han D, Severson RK, et al. Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control. 2002 Feb;13(1):15-25.
  375. Reardon DC. The abortion and mental health controversy: A comprehensive literature review of common ground agreements, disagreements, actionable recommendations, and research opportunities. SAGE Open Medicine. 2018;6:2050312118807624.
  376. Major B, Appelbaum M, Beckman L, et al. Abortion and mental health: Evaluating the evidence. The American Psychologist. 2009 Dec;64(9):863-90.
  377. Dingle K, Alati R, Clavarino A, et al. Pregnancy loss and psychiatric disorders in young women: an Australian birth cohort study. The British Journal of Psychiatry : the Journal of Mental Science. 2008;193(6):455–460.
  378. Coleman PK. Abortion and mental health: quantitative synthesis and analysis of research published 1995-2009. The British Journal of Psychiatry : the Journal of Mental Science. 2011;199(3):180–186.
  379. Ajrouche R, Rudant J, Orsi L, et al. Maternal reproductive history, fertility treatments and folic acid supplementation in the risk of childhood acute leukemia: the ESTELLE study. Cancer Causes Control. 2014;25(10):1283–1293.
  380. Zou G, Sha X. [Effects of Birth Order, Maternal Abortion and Mode of Delivery on Childhood Acute Leukemia Risk: A Meta-Analysis]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2014;52(3):209–214.
  381. Karalexi MA, Dessypris N, Skalkidou A, et al. Maternal fetal loss history and increased acute leukemia subtype risk in subsequent offspring: a systematic review and meta-analysis. Cancer Causes Control. 2017;28(6):599–624.
  382. Feng Y, Wang S, Zhao L, Yu D, Hu L, Mo X. Maternal reproductive history and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Pediatric Cardiology. 2015;36(2):253–263.
  383. Steinberger EK, Ferencz C, Loffredo CA. Infants with single ventricle: a population-based epidemiological study. Teratology. 2002;65(3):106–115.
  384. Bracken MB, Holford TR. Induced abortion and congenital malformations in offspring of subsequent pregnancies. American Journal of Epidemiology. 1979;109(4):425–432.
  385. Desta M, Tadese M, Kassie B, Gedefaw M. Determinants and adverse perinatal outcomes of low birth weight newborns delivered in Hawassa University Comprehensive Specialized Hospital, Ethiopia: a cohort study. BMC Research Notes. 2019 Mar 4;12(1):118.
  386. Ancel PY, Lelong N, Papiernik E, et al. History of induced abortion as a risk factor for preterm birth in European countries: results of the EUROPOP survey. Human Reproduction. 2004;19(3):734–740.
  387. Hemmingsen CH, Kjaer SK, Jezek AH, et al. Maternal use of hormonal contraception and risk of childhood ADHD: a nationwide population-based cohort study. European Journal of Epidemiology. 2020 Sep;35(9):795-805.
  388. Leelakanok N, Methaneethorn J. A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Clinical Drug Investigation. 2020;40(5):395‐420.
  389. Institute for Safe Medication Practices. Safety profiles of newer contraceptives. January 24, 2018. https://www.ismp.org/sites/default/files/attachments/2018-01/2017Q2.pdf. Accesed Jan 14 2020.
  390. Nelson AL, Massoudi N. New developments in intrauterine device use: focus on the US. Open Access Journal of Contraception. 2016;7:127-141.
  391. Menon S. Long-Acting Reversible Contraception: Specific Issues for Adolescents. Pediatrics. 2020 August. 146 (2) e2020007252.
  392. Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstetrics & Gynecology. 2017 Nov;130(5):e251-e269.
  393. Agulles Simó P. Efecto Abortivo de los Anticonceptivos Hormonales: Una Revisión [Abortifacient effect of hormonal contraceptives: a review]. Cuadernos de Bioética : Revista Oficial de la Asociación Española de Bioética y Ética Médica. 2015 Jan-Apr;26(86):69-109.
  394. Dinehart E, Lathi RB, Aghajanova L. Levonorgestrel IUD: is there a long-lasting effect on return to fertility?. Journal of Assisted Reproduction and Genetics. 2020;37(1):45-52.
  395. Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling. International Journal of Women’s Health.2016;8:589-598.
  396. Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception. 1995 Jun;51(6):359-65.
  397. Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and efects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertility and Sterility. 2014. Jun;101(6):1656-62.e1-4.
  398. Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years’ use of a levonorgestrel IUD. Advances in contraception : the official journal of the Society for the Advancement of Contraception. 1995 Jun;11(2):85-95.
  399. Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. American Journal of Obstetrics and Gynecology. 2002 Dec;187(6):1699-708.
  400. Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Preference and Adherence. 2013 Aug 9;7:777-85.
  401. Xiao B, Zeng T, Wu S, Sun H, Xiao N. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception. 1995 Jun;51(6):359-65.
  402. Tochigi H, Kajihara T, Mizuno Y, et al. Loss of miR-542-3p enhances IGFBP-1 expression in decidualizing human endometrial stromal cells. Scientific Reports. 2017;7:40001.
  403. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception. 2007 Jun;75(6 Suppl):S93-8.
  404. Smith-McCune K, Thomas R, Averbach S, et al. Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome. Scientific Reports. 2020;10(1):6888.
  405. Li C, Wu YT, Zhu Q, et al. TRPV4 is involved in levonorgestrel-induced reduction in oviduct ciliary beating. The Journal of Pathology. 2019;248(1):77–87.
  406. Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Preference and Adherence. 2013;7:777-785.
  407. Patseadou M, Michala L. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far? Archives of Gynecology and Obstetrics. 2017 Mar;295(3):529-541.
  408. Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertility and Sterility. 2005 Feb;83(2):398-404.
  409. Raudaskoski T, Tapanainen J, Tomás E. et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG : an International Journal of Obstetrics and Gynaecology. 2002 Feb;109(2):136-44.
  410. Haimov-Kochman R, Amsalem H, Adoni A. et al. Management of a perforated levonorgestrel-medicated intrauterine device–a pharmacokinetic study: case report. Human Reproduction. 2003 Jun;18(6):1231-3.
  411. Pakarinen P, Lähteenmäki P, Rutanen EM. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstetricia et Gynecologica Scandinavica. 1999 May;78(5):423-8.
  412. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. The New England Journal of Medicine. 2017 Dec 7;377(23):2228-2239.
  413. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Research : BCR. 2017;19:10.
  414. Soini T, Hurskainen R, Grénman S. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. 2016;55(2):188-92.
  415. Cheema HI, Gupta A. Levonorgestrel-Releasing Intrauterine Device-Related Acute Liver Injury. Case Reports in Gastroenterology. 2017;11(3):742-747.
  416. Spivak M, et al. Development of liver adenomatosis following utilization of progesterone containing intrauterine device. Endocrine Society’s 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago.
  417. Aleknaviciute J, Tulen JHM, De Rijke YB, et al. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 2017 Jun;80:39-45.
  418. Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica. 2020 Aug;99(8):970-982.
  419. Siegelmann-Danieli N, Katzir I, Landes JV, et al. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Research and Treatment. 2018 Jan;167(1):257-262.
  420. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. The New England Journal of Medicine. 2017 Dec 7;377(23):2228-2239.
  421. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Research : BCR. 2017;19:10.
  422. Soini T, Hurskainen R, Grénman S. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. 2016;55(2):188-92.
  423. Trinh XB, Tjalma WA, Makar AP. et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility. 2008 Jul;90(1):17-22.
  424. Loopik DL, IntHout J, Melchers WJG, Massuger LFAG, Bekkers RLM, Siebers AG. Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study. European Journal of Cancer. 2020 Jan;124:102-109.
  425. Averbach S, Silverberg MJ, Leyden W, et al. Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. Contraception. 2018 Apr 17; S0010-7824(18)30144-6. .
  426. Averbach S, Silverberg MJ, Leyden W, et al. Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. Contraception. 2018 Apr 17; S0010-7824(18)30144-6.
  427. Spotnitz ME, Natarajan K, Ryan PB, Westhoff CL. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users. Obstetrics and Gynecology. 2020 Feb;135(2):319-327.
  428. Shanmugasundaram U, Hilton JF, Critchfield JW, et al. Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium. American Journal of Reproductive Immunology. 2016 Aug ;76(2):137-148.
  429. Smith-McCune K, Thomas R, Averbach S, et al. Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome. Scientific Reports. 2020;10(1):6888.
  430. Bosch FX, Broker TR, Forman D. et al. Comprehensive control of human papillomavirus infections and related diseases. See comment in PubMed Commons belowVaccine. 2013 Dec 31;31 Suppl 7:H1-31.
  431. Tomaić V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Mok SC, ed. Cancers. 2016 Oct;8(10):95.
  432. Walline HM, Komarck C, McHugh JB, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and, oral cavity cancers: Comparison of multiple methods. JAMA Otolaryngology– Head & Neck Surgery. 2013 Dec;139(12):1320-1327.
  433. Andersen L, Friis S, Hallas J. et al. Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. British Journal of Clinical Pharmacology. 2015;79(4):677-684.
  434. Supartoto A, Sasongko MB, Respatika D, et al. Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females. Frontiers in Oncology. 2019 Jan 9;8:651.
  435. Wigertz A, Lönn S, Mathiesen T. et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. American Journal of Epidemiology. 2006 Oct 1;164(7):629-36.
  436. Harland TA, Freeman JL, Davern M, et al. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. Journal of Neuro-oncology. 2018 Jan;136(2):327-333.
  437. Malaize H, Samoyeau T, Zanello M, et al. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. Journal of Neuro-Oncology. 2021 Apr;152(2):279-288.
  438. Apra, C., Roblot, P., Alkhayri, A. et al. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas. Journal of Neuro-Oncology. 149, 95–101 (2020).
  439. Heliövaara-Peippo S, Oksjoki R, Halmesmäki K, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: a 10-year follow-up of a randomised trial. Maturitas. 2011 Aug;69(4):354-8.
  440. Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstetricia et Gynecologica Scandinavica. 1999 Sep;78(8):716-21.
  441. Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017 Mar;210:22-28.
  442. Modesto W, de Nazaré Silva dos Santos P, Correia VM, et al. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. The European Journal of Contraception & Reproductive Health Care. 2015 Feb;20(1):57-63.
  443. Dal’Ava N, Bahamondes L, Bahamondes MV, et al. Body weight and composition in users of levonorgestrel-releasing intrauterine system. Contraception. 2012 Oct;86(4):350-3.
  444. Kayikcioglu F, Gunes M, Ozdegirmenci O, Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception. 2006 May;73(5):528-31. Epub 2006 Mar 23.
  445. GBD 2013 Risk Factors Collaborators. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015;386(10010):2287-2323.
  446. Bergendal A, Persson I, Odeberg J. et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstetrics and Gynecology. 2014 Sep;124(3):600-9.
  447. Columbia University Department of Neurology. Increased Intracranial Pressure (ICP) Headache. http://columbianeurology.org/neurology/staywell/document.php?id=42076. Accesed 6 March 2018.
  448. Hardin JS, Ramakrishnaiah RH, Pemberton JD, et al. Idiopathic Intracranial Hypertension Progressing to Venous Sinus Thrombosis, Subarachnoid Hemorrhage, and Stroke. Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society. 2018 Mar;38(1):60-64
  449. Rai R, Kirk B, Sanders J., et al. The relationship between the levonorgestrel-releasing intrauterine system and idiopathic intracranial hypertension. Investigative Ophthalmology & Visual Science. 2015. 2015; 56(7):2228.
  450. Etminan M, Luo H, Gustafson P. Risk of intracranial hypertension with intrauterine levonorgestrel. Therapeutic Advances in Drug Safety. 2015;6(3):110-113.
  451. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. The American Journal of Psychiatry. 2018 Apr 1;175(4):336-342.
  452. Slattery J, Morales D, Pinheiro L, Kurz X. Cohort Study of Psychiatric Adverse Events Following Exposure to Levonorgestrel-Containing Intrauterine Devices in UK General Practice. Drug Safety. 2018 Oct;41(10):951-958.
  453. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018;13(3):e0194773.
  454. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016 Nov 1;73(11):1154-1162.
  455. Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception. 2012 Apr;17(2):106-18.
  456. Aleknaviciute J, Tulen JHM, De Rijke YB, et al. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 2017 Jun;80:39-45.
  457. Smith K, Nayyar S, Rana T, et al. Do Progestin-Only Contraceptives Contribute to the Risk of Developing Depression as Implied by Beta-Arrestin 1 Levels in Leukocytes? A Pilot Study. International Journal of Environmental Research and Public Health. 2018;15(9):1966.
  458. Teal SB, Turok DK, Chen BA, et al. Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System. Obstetrics and Gynecology. 2019;133(1):63-70.
  459. McCarthy EA, Jagasia N, Maher P, et al. Ultrasound-guided hysteroscopy to remove a levonorgestrel intrauterine system in early pregnancy. Contraception. 2012 Nov;86(5):587-90.
  460. Simpson JL, Holzgreve W. Genetic counseling and genetic screening. In: Gabbe SG, Niebyl JR, Simpson JL, editors. Obstetrics: normal andproblem pregnancies. 5th ed. Philadelphia: Churchill Livingstone; 2007. p. 139–51.
  461. DRUGBANK. Levonorgestrel. https://www.drugbank.ca/drugs/DB00367. Accessed 30 October 2019.
  462. GeneCards. SRD5A1 gene. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SRD5A1. Accessed 21 October 2019.
  463. Han LW, Gao C, Mao Q. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(8):817–829.
  464. UniProt. Cytochrome P450 2C19. https://www.uniprot.org/uniprot/P33261. Accessed 24 January 2020.
  465. Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death & Disease. 2011;2(8):e193.
  466. Schatz F, Guzeloglu-Kayisli O, Arlier S, et al. The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Human Reproduction Update. 2016;22(4):497–515.
  467. Sadler TW, Rasmussen SA. Examining the evidence for vascular pathogenesis of selected birth defects. American Journal of Medical Genetics. Part A. 2010 Oct;152A(10):2426-36.
  468. Salinas-Torres VM, Salinas-Torres RA, Cerda-Flores RM, et al. Genetic variants conferring susceptibility to gastroschisis: a phenomenon restricted to the interaction with the environment? Pediatric Surgery International. Mar 2018, 34(5):505-514.
  469. Salinas-Torres VM, Salinas-Torres RA, Cerda-Flores RM, et al. A clinical-pathogenetic approach on associated anomalies and chromosomal defects supports novel candidate critical regions and genes for gastroschisis. Pediatric Surgery International. 2018 Sep;34(9):931-943.
  470. Lubinsky M. A vascular and thrombotic model of gastroschisis. American Journal of Medical Genetics. Part A. 2014 Apr;164A(4):915-7.
  471. Lubinsky M. Gastroschisis as a thrombotic disruption. Birth Defects Research. 2019 Jun 1;111(10):621.
  472. Roopa BA, Loganath A, Singh K. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Human Reproduction. 2003 Sep;18(9):1809-19.
  473. Vargas MF, Tapia-Pizarro AA, Henríquez SP, et al. Effect of single post-ovulatory administration of levonorgestrel on gene expression profile during the receptive period of the human endometrium. Journal of Molecular Endocrinology. 2012;48(1):25-36.
  474. Salmi A, Pakarinen P, Peltola AM, et al. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Molecular Human Reproduction. 1998 Dec;4(12):1110-5.
  475. Pubchem. Levonorgestrel. https://pubchem.ncbi.nlm.nih.gov/compound/Levonorgestrel. Accessed 5 April 2020.
  476. Berenson AB, Tan A, Hirth JM. Complications and continuation rates associated with 2 types of long-acting contraception. American Journal of Obstetrics and Gynecology. 2015;212(6):761.e1–761.e7618.
  477. Fulkerson Schaeffer S, Gimovsky AC, Aly H, Mohamed MA. Pregnancy and delivery with an intrauterine device in situ: outcomes in the National Inpatient Sample Database. The Journal of Maternal-Fetal & Neonatal Medicine. 2019 Mar;32(5):798-803.
  478. Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017 Mar;210:22-28.
  479. Teal SB, Turok DK, Chen BA, et al. Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System. Obstetrics and Gynecology. 2019;133(1):63-70.
  480. Backman T, Rauramo I, Huhtala S, et al. Pregnancy during the use of levonorgestrel intrauterine system. American Journal of Obstetrics and Gynecology. 2004 Jan;190(1):50-4.
  481. Li C, Wu YT, Zhu Q, et al. TRPV4 is involved in levonorgestrel-induced reduction in oviduct ciliary beating. The Journal of Pathology. 2019;248(1):77–87.
  482. Zgliczynska M, Kocaj K, Szymusik I, et al. Levonorgestrel-Releasing Intrauterine System as a Contraceptive Method in Nulliparous Women: A Systematic Review. Journal of Clinical Medicine.2020;9(7):2101.
  483. Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017 Mar;210:22-28.
  484. Perriera LK, Blumenthal PD, Stuart GS, et al.  Return of Spontaneous Menses and Fertility After Removal of the Liletta Levonorgestrel Intrauterine System [4O]. Obstetrics & Gynecology. 2016 May;127:123S–124S.
  485. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992 Dec;46(6):575-84.
  486. Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clinical Endocrinology. 1982 Dec;17(6):529-36.
  487. Chai M, Su S, Dong B. Morphological and Ultrastructural Changes in Human Endometrium Following Low-Dose Levonorgestrel Contraceptive Intrauterine Systems (LNG-IUS-12) 13.5 mg. Journal of Obstetrics and Gynaecology of India.2015;65(5):323-327.
  488. Sitruk-Ware R, Inki P. The levonorgestrel intrauterine system: long-term contraception and therapeutic effects. Women’s Health. 2005 Sep;1(2):171-82.
  489. Hejmadi RK, Chaudhri S, Ganesan R, Rollason TP. Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases. International Journal of Surgical Pathology. 2007 Apr;15(2):148-54.
  490. Goldfien GA, Barragan F, Chen J, et al. Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix. Reproductive Sciences. 2015;22(7):814-828.
  491. Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Human Reproduction. 2000 Aug;15 Suppl 3:162-72.
  492. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Human Reproduction. 2000 Aug;15 Suppl 3:173-81.
  493. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Human Reproduction. 2000 Aug;15 Suppl 3:173-81
  494. Engemise SL, Willets JM, Taylor AH, et al. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2011 Jul;157(1):101-6.
  495. Vereide AB, Kaino T, Sager G, et al. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecologic Oncology. 2006 May;101(2):214-23.
  496. Smith-McCune K, Thomas R, Averbach S, et al. Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome. Scientific Reports. 2020;10(1):6888.
  497. Dinehart E, Lathi RB, Aghajanova L. Levonorgestrel IUD: is there a long-lasting effect on return to fertility?. Journal of Assisted Reproduction and Genetics. 2020;37(1):45-52.
  498. Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contraception and Reproductive Medicine. 2018 Jul 23;3:9.
  499. Toro CA, Aylwin CF, Lomniczi A. Hypothalamic epigenetics driving female puberty. Journal of Neuroendocrinology.2018;30(7):e12589.
  500. Lomniczi A, Wright H, Ojeda SR, et al. Epigenetic regulation of female puberty. Frontiers in Neuroendocrinology. 2015 Jan;36:90-107.
  501. Dinehart E, Lathi RB, Aghajanova L. Levonorgestrel IUD: is there a long-lasting effect on return to fertility?. Journal of Assisted Reproduction and Genetics. 2020;37(1):45-52.
  502. Menon S. Long-Acting Reversible Contraception: Specific Issues for Adolescents. Pediatrics. 2020 August. 146 (2) e2020007252.
  503. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstetrics and Gynecology. 2012 Oct;120(4):983-8.
  504. Schwartz BI, Alexander M, Breech LL. Levonorgestrel Intrauterine Device Use for Medical Indications in Nulliparous Adolescents and Young Adults. The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine. 2021 Feb;68(2):357-363.
  505. Aslam N, Blunt S, Latthe P. Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2010;30(5):489-91.
  506. Schwartz BI, Alexander M, Breech LL. Intrauterine Device Use in Adolescents With Disabilities. Pediatrics. 2020;146(2):e20200016.
  507. Aslam N, Blunt S, Latthe P. Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2010;30(5):489-91.
  508. Gadelha Da Costa A, Filho FM, Ferreira AC. et al. Uterine volume in adolescents. Ultrasound in Medicine & Biology. 2004 Jan;30(1):7-10.
  509. Kelsey TW, Ginbey E, Chowdhury MM, et al. A Validated Normative Model for Human Uterine Volume from Birth to Age 40 Years. Lambalk CB, ed. PLoS ONE. 2016;11(6):e0157375.
  510. Alton TM, Brock GN, Yang D. et al. Retrospective review of intrauterine device in adolescent and young women. Journal of Pediatric and Adolescent Gynecology. 2012 Jun;25(3):195-200.
  511. Behringer T, Reeves MF, Rossiter B, Chen BA, Schwarz EB. Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception. 2011 Nov;84(5):e5-e10.
  512. Berenson AB, Tan A, Hirth JM. Complications and continuation rates associated with 2 types of long-acting contraception. American Journal of Obstetrics and Gynecology. 2015 Jun;212(6):761.e1-8.
  513. Colaprico A, Olsen C, Bailey MH, et al. Interpreting pathways to discover cancer driver genes with Moonlight. Nature Communications. 2020;11(1):69.
  514. Mohammadizadeh F, Hani M, Ranaee M, Bagheri M. Role of cyclin D1 in breast carcinoma. Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences. 2013;18(12):1021-1025.
  515. Park J, Schlederer M, Schreiber M, et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015;6(24):20697-20710.
  516. Roth ChL and Mastronardi C. Early Puberty Onset and Female Cancers–Is There a Link? In: Moorland MT(ed.). Cancer in Female Adolescents. New York: Nova Science Publishers; 2008:212.
  517. Lipton ML, Chen K, Worley S, et al. Oral Contraceptive Use Is Associated with Smaller Hypothalamic Volumes in Healthy Women. 105th Scientific Assembly and Annual Meeting of the Radiological Society of North America-RSNA 2019. https://press.rsna.org/timssnet/media/pressreleases/14_pr_target.cfm?id=2136. Accessed 3 March 2021.
  518. Petersen N, Kearley NW, Ghahremani DG, et al. Effects of oral contraceptive pills on mood and magnetic resonance imaging measures of prefrontal cortical thickness. Molecular Psychiatry. 2021 Jan 8.
  519. Petersen N, Touroutoglou A, Andreano JM, Cahill L. Oral contraceptive pill use is associated with localized decreases in cortical thickness. Human Brain Mapping. 2015;36(7):2644-54.
  520. Lisofsky N, Riediger M, Gallinat J, et al. Hormonal contraceptive use is associated with neural and affective changes in healthy young women. NeuroImage. 2016 Jul 1;134:597-606.
  521. Siegelmann-Danieli N, Katzir I, Landes JV, et al. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspectiv. Breast Cancer Research and Treatment. 2018 Jan;167(1):257-262.
  522. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. The New England Journal of Medicine. 2017 Dec 7;377(23):2228-2239.
  523. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Research : BCR. 2017;19:10.
  524. Slattery J, Morales D, Pinheiro L, Kurz X. Cohort Study of Psychiatric Adverse Events Following Exposure to Levonorgestrel-Containing Intrauterine Devices in UK General Practice. Drug Safety. 2018 Oct;41(10):951-958.
  525. Bosco-Lévy P, Gouverneur A, Langlade C, et al. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study. Contraception. 2019 Jun;99(6):345-349.
  526. Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. PLoS One. 2018;13(3):e0194773.
  527. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016 Nov 1;73(11):1154-1162.
  528. Lindberg M, Foldemo A, Josefsson A, Wiréhn AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception. 2012 Apr;17(2):106-18.
  529. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. The American Journal of Psychiatry. 2018 Apr 1;175(4):336-342.
  530. Rowlands S, Ingham R. Long-acting reversible contraception: conflicting perspectives of advocates and potential users. BJOG. 2017 Sep;124(10):1474-1476.
  531. Kaitz M, Mankuta D, Mankuta L. Long-acting reversible contraception: A route to reproductive justice or injustice. Infant Mental Health Journal. 2019;40(5):673-689.
  532. Kuby G. Globálna sexuálna revolúcia. Bratislava : Lúč, 2013, s. 35-72.
  533. Zimbardo P, Coulombová N. Odpojený muž. Praha : Grada, 2017, s. 37-40, 79-104.
  534. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 84, 87-90.
  535. Spaemann R. Hovoríme o etike. Bratislava : Don Bosco, 1994, s. 17-23, 29-30; Kreft P. Návrat k čnosti. Bratislava : Redemptoristi, 2007, s. 169-174.
  536. Lewis CS. Čtyři lásky, Praha : Návrat domů, 1997, s. 72-73; Baggio AM. Hľadať si tvár. Bratislava : Nové mesto, 1996, s. 69-75.
  537. Weyler R. The end of infinite growth. https://www.greenpeace.org/international/story/26506/the-end-of-infinite-growth/. Accessed 15 November 2019.
  538. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 67-72.
  539. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 102-105.
  540. Berďajev N. O otroctví a svobodě člověka. Praha : OIKOYMENH, 1997, s. 180, 188-189.
  541. Wojtyla K. Láska a zodpovednosť. Bratislava : Metodicko-pedagogické centrum, 2003, s. 136-141; Anderson C, Granados J. Povolaní milovať. Bratislava : Redemptoristi, 2014, s. 120-121.
  542. Lorenz K. Osm smrtelných hříchů, Praha : Academia, 2000, s. 32-38.
  543. Anderson C, Granados J. Povolaní milovať. Bratislava : Redemptoristi, 2014, s. 156-160; Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 108-109.
  544. Kreft P. Návrat k čnosti. Bratislava : Redemptoristi, 2007, s. 174-178.
  545. Puss A. Love story & skutočný svet. Trnava : Dobrá kniha, 2002, s. 25-26.
  546. Smelý I. Nový morálny kód. Prešov : VMV, 2003, s.102-106.
  547. Puss A. Love story & skutočný svet. Trnava : Dobrá kniha, 2002, s. 25.
  548. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 164.
  549. Anderson C, Granados J. Povolaní milovať. Bratislava : Redemptoristi, 2014, s. 186-190.
  550. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 153-157.
  551. Melina L. Kultúra rodiny. Reč lásky. Bratislava : Don Bosco, 2014, s. 157-160.
  552. Kippley JS. Umění přirozeného plánování rodičovství. Olomouc : Matice CM, 1995, s. 63-78.
Ďakujeme za zdieľanie a šírenie osvety o problematickosti antikoncepcie.